Array BioPharma Gets $85M From Novartis
Boulder-based Array Biopharma said this morning that it has received $85M from Novartis, as part of a licensing deal with the biotech giant. Array Biophrma said it has granted Novartis a global, exclusive license to its binimetinib product, and global rights to its encorafenib product. Both of those drugs are being targeted for treating cancer.
posted on Monday, March 2, 2015
Related companies:
Array Biopharma
Related stories:
> Array BioPharma Appoints New CFO
> Array BioPharma, VentiRx In License Deal
> Array BioPharma Hits Milestone
> Array BioPharma Licenses Rights To Amgen
> Array BioPharma Raises $18M From Realty Sale
Techrockies.com Home